Gilead Sciences, Inc. Stock price

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
73.01 USD +0.83% Intraday chart for Gilead Sciences, Inc. -1.31% -9.88%
Sales 2024 * 27.51B Sales 2025 * 28.03B Capitalization 90.95B
Net income 2024 * 6.54B Net income 2025 * 6.86B EV / Sales 2024 * 3.74 x
Net Debt 2024 * 11.84B Net Debt 2025 * 4.96B EV / Sales 2025 * 3.42 x
P/E ratio 2024 *
14 x
P/E ratio 2025 *
13.2 x
Employees 18,000
Yield 2024 *
4.3%
Yield 2025 *
4.48%
Free-Float 99.86%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.83%
1 week-1.31%
Current month+1.26%
1 month-0.01%
3 months-9.16%
6 months-3.36%
Current year-9.88%
More quotes
1 week
72.11
Extreme 72.11
73.23
1 month
71.92
Extreme 71.92
76.21
Current year
71.37
Extreme 71.37
87.87
1 year
71.37
Extreme 71.37
87.87
3 years
57.17
Extreme 57.165
89.74
5 years
56.56
Extreme 56.56
89.74
10 years
56.56
Extreme 56.56
123.37
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 19-02-28
Director of Finance/CFO 54 15-12-31
Chief Tech/Sci/R&D Officer - 21-04-11
Members of the board TitleAgeSince
Director/Board Member 69 20-10-16
Director/Board Member 71 17-12-31
Director/Board Member 65 Jan. 31
More insiders
Date Price Change Volume
24-03-27 73.01 +0.83% 7,747,590
24-03-26 72.41 -0.23% 5,362,890
24-03-25 72.58 -0.04% 5,543,898
24-03-22 72.61 -0.66% 7,730,620
24-03-21 73.09 -1.20% 5,836,856

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
73.01 USD
Average target price
86.45 USD
Spread / Average Target
+18.41%
Consensus
  1. Stock
  2. Equities
  3. Stock Gilead Sciences, Inc. - Nasdaq